Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Inhibition of Myopia Progression With Optical Devices

7 juillet 2026 mis à jour par: Barcsay-Veres Amarilla, Semmelweis University

This observational study aims to determine whether optical devices designed to slow myopia progression and/or environmental factors can prevent myopia progression in the pediatric and adolescent myopic population.

The study aims to answer the following questions:

  1. How does myopia progression change with age while wearing myopia progression control glasses?
  2. How does myopia progression change while wearing myopia progression-control glasses when environmental factors, such as time spent outdoors and place of residence, are taken into account?
  3. How does myopia progression change at different ages while wearing myopia progression control glasses given a family history of myopia? This will be a self-controlled observational study. Participants who are myopic after cycloplegic refraction will be prescribed DIMS glasses. DIMS stands for "defocus incorporated multiple segments," a specialized optical technology used in spectacle lenses to slow nearsightedness progression in children.

Patients will keep a diary of their subjective symptoms and environmental factors, e.g., time spent outdoors and screen time.

Patients will visit the clinic once every six months for checkups and the following tests:

  • Best corrected visual acuity test
  • Stereopsis
  • Automatic refractometry
  • Bulbar axial length measurement

In a follow-up study, researchers will compare myopia progression with environmental and baseline factors to learn about the long-term effects of DIMS lenses on myopia progression.

Aperçu de l'étude

Statut

Recrutement

Les conditions

Intervention / Traitement

Description détaillée

As an observational study we aim to examine the effects of D.I.M.S. lens's daily wear on myopia progression in relation to the environmental factors.

Our pediatric and adolescent myopic population is selected as follows:

Inclusion Criteria:

  • Participants must be between 6 and 15 years of age at the start of myopia progression treatment
  • Caucasian ethnicity
  • Refractive error measured under cycloplegia, expressed as spherical equivalent: between -0.50 Dsph and -10.0 Dsph
  • Wearing myopia-control glasses during waking hours
  • Willing to Participate in follow-up examinations up to 24 weeks

Exclusion criteria:

  • pathological myopia (e.g., myopia onset before age 6, Stickler syndrome)
  • preterm infants born before 32 weeks of gestation
  • previous eye-opening surgery (e.g., lens extraction)
  • Traumatic eye injury
  • Known connective tissue disorder (e.g., Marfan syndrome)
  • Irregular or improper use of progressive-lens glasses
  • Failure to attend the follow-up examinations scheduled

In the self-controlled observational study the myopic participants are wearing during day time DIMS glasses. DIMS stands for "defocus incorporated multiple segments," a specialized optical technology used in spectacle lenses to slow nearsightedness progression in children. DIMS glasses not only correct the refractive errror but also provide a circular defocus zone to avoid periferial retinal defocus.

Patients will keep a diary of their subjective symptoms and environmental factors, e.g., time spent outdoors and screen time, subjective symptoms.

Patients will visit the clinic once every six months for checkups and the following tests:

  • Best corrected visual acuity test
  • Stereopsis
  • Automatic refractometry
  • Bulbar axial length measurement These measurements and tests are part of the regular ophthalmological follow-up examinations.

The study aims to answer the following questions:

  1. How does myopia progression change with age while wearing myopia progression control glasses?
  2. How does myopia progression change while wearing myopia progression-control glasses when environmental factors, such as time spent outdoors and place of residence, are taken into account?
  3. How does myopia progression change at different ages while wearing myopia progression control glasses given a family history of myopia? Statistical analysis plan includes non-parametric t-test, one way and two way ANOVA tests.

Type d'étude

Observationnel

Inscription (Estimé)

50

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

      • Budapest, Hongrie, 1085
        • Recrutement
        • Semmelweis University Ophthalmology Department
        • Contact:
        • Contact:
        • Sous-enquêteur:
          • Otto A Maneschg, PhD
        • Sous-enquêteur:
          • Amarilla Barcsay-Veres, PhD

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Enfant

Accepte les volontaires sains

Non

Méthode d'échantillonnage

Échantillon de probabilité

Population étudiée

Participants (between 6 and 15 years of age) are wearing myopia progression treatment , namely D.I.M.S. lenses while they are awake. The wear these glasses to correct refractive error and to slow down myopia progression.

At enrollment the refractive error measured under cycloplegia, expressed as spherical equivalent must be: between -0.50 Dsph and -10.0 Dsph.

La description

Inclusion Criteria:

  • • Participants must be between 6 and 15 years of age at the start of myopia progression treatment

    • Caucasian ethnicity
    • Refractive error measured under cycloplegia, expressed as spherical equivalent: between -0.50 Dsph and -10.0 Dsph
    • Wearing myopia-control glasses while awake
    • Participation in follow-up examinations every 6 months

Exclusion Criteria:

  • • Pathological myopia (e.g., myopia onset before age 6, Stickler syndrome)

    • Premature birth before the 32nd week of gestation
    • Previous eye-opening surgery (e.g., lens removal)
    • Traumatic eye injury
    • Known connective tissue disorder (e.g., Marfan syndrome)
    • Irregular or improper use of progressive-lens glasses
    • Failure to attend the follow-up examinations scheduled every 6 months

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

Cohortes et interventions

Groupe / Cohorte
Intervention / Traitement
Myopic cohort

Inclusion Criteria:

  • Participants must be between 6 and 15 years of age at the start of myopia progression treatment
  • Caucasian ethnicity
  • Refractive error measured under cycloplegia, expressed as spherical equivalent: between -0.50 Dsph and -10.0 Dsph
  • Wearing myopia-control glasses while awake
  • Participation in follow-up examinations every 6 months

Exclusion criteria:

  • Pathological myopia (e.g., myopia onset before age 6, Stickler syndrome)
  • Premature birth before the 32nd week of gestation
  • Previous eye-opening surgery (e.g., lens removal)
  • Traumatic eye injury
  • Known connective tissue disorder (e.g., Marfan syndrome)
  • Irregular or improper use of progressive-lens glasses
  • Failure to attend the follow-up examinations scheduled every 6 months
DIMS (Defocus Incorporated Multiple Segments) lenses wearing while awake
D.I.M.S. lenses are worn like normal glasses to correct myopia and, beyond that, their special design is intended to slow myopia progression via defocus lenslets. There is targeted myopic defocus produced by the mid-peripheral lenslets with positive power to inhibit eye length growth.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Best corrected visual acuity test
Délai: up to 24 week
Zero is equivalent to no vision and 1.0 indicates the best visual acuity in decimal scale. Distance and near visual acuity is measured under standard conditions
up to 24 week
Bulbar axial length measurement
Délai: up to 24 week
It is defined as the distance from the anterior surface of the cornea to the retinal pigment epithelium, measured in millimeters using optical device. An increase in axial length is characteristic of the elongation of the eye.
up to 24 week

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Stereopsis
Délai: up to 24 week
stereopsis test (depth perception test) measures how well the eyes create three-dimensional vision. The precision of depth perception is measured in seconds of arc (arcsec) using a test plate. If stereoscopic vision is present, the smaller the angle, the more refined the stereopsis.
up to 24 week

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Chercheur principal: Zoltan Zs Nagy, Professor, Semmelweis University Ophthalmology Department

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

2 juin 2026

Achèvement primaire (Estimé)

31 mai 2027

Achèvement de l'étude (Estimé)

31 mai 2027

Dates d'inscription aux études

Première soumission

27 juin 2026

Première soumission répondant aux critères de contrôle qualité

7 juillet 2026

Première publication (Réel)

13 juillet 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

13 juillet 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

7 juillet 2026

Dernière vérification

1 juillet 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • SE-RKEB 222/2026

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Oui

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .